Patients Were 3.1x More Likely to Reach Treatment Goals When Tested with PrismRA® Demonstrates Significantly Superior Outcomes Compared to Standard of Care in 3,348 Patient Analysis WALTHAM, Mass. (November 10, 2022) – Scipher Medicine announced data validating...
Collaboration Achieves Key Milestones After Preclinical Validation Work, Triggers Milestone Payment to Scipher WALTHAM, Mass. (May 24, 2022) – Scipher Medicine today announced that Galapagos (Euronext & NASDAQ: GLPG) has exercised its option to in-license...
Patients Show Nearly Two-fold Clinical Improvement when Treatment Selection Informed by PrismRA; Predictive Blood Test Could Improve Efficiency in Health Care Spending WALTHAM, Mass. (April 28, 2022) – Scipher Medicine, a precision immunology company matching...
WALTHAM, Mass. (Feb. 28, 2022) – Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced Chief Technology Officer Slava Akmaev, Ph.D., will participate in a virtual panel at the Truist Securities...
WALTHAM, Mass. (Feb. 11, 2022) – Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced that Chief Financial Officer John Strumbos will participate in the virtual 11th Annual SVB Leerink...
